Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- ATTR-CM evidence often conflicts because studies ask different questions in different populations.
- Clinical trial and real-world evidence should be interpreted within their respective study settings.
- Endpoint choice and follow-up horizon may influence the observed treatment outcomes.
- The right response is narrower, context-specific interpretation, not averaging studies with different designs and populations.
Why ATTR-CM Studies Appear to Conflict
ATTR-CM studies may appear to produce conflicting findings because they differ in study objectives, patient populations, endpoints, and duration of follow-up rather than because they reflect differences in the underlying disease biology. Individual studies may therefore be internally valid while addressing different clinical questions, highlighting the importance of interpreting results within the context of each study design.
Why Trial Clarity and Routine Clinical Practice Are Not the Same View
Controlled trials and routine care data provide complementary evidence from different clinical settings. Placebo-controlled trials such as ATTR-ACT and ATTRibute-CM enroll defined, adjudicated populations, so treatment effects and biomarker changes are evaluated under more controlled conditions. Older, more comorbid, less persistent routine-care populations introduce greater comorbidity burden and variations in healthcare delivery and treatment adherence, so the same therapy can produce different observed clinical outcomes. Neither is wrong; they answer different questions, as real-world evidence makes explicit.
Why the Right Response Is Narrower Interpretation, Not Inappropriate Direct Comparison
Findings from ATTR-CM studies should be interpreted within the context of the study population, duration of follow-up, exposure to treatment, and diagnostic criteria rather than directly comparing or combining results from studies with substantially different designs. Evidence from different clinical settings is most informative when interpreted in the context of the conditions under which it was generated. Careful consideration of study design, patient characteristics, and clinical setting enables clinicians to apply the findings appropriately in practice.
Frequently Asked Questions
Why does ATTR-CM evidence seem to conflict?
ATTR-CM evidence seems to conflict because studies differ in population, endpoint, and follow-up window. Results can look inconsistent while each remains internally valid, so the apparent differences usually reflect differences in study design and patient populations rather than differences in disease biology.
Are trial and real-world results interchangeable?
No. Controlled trials enroll defined, adjudicated populations; routine care data include older, comorbid, patients with greater variability in treatment adherence. They answer different questions and shouldn't be merged into one verdict.
What is the right way to handle conflicting results?
Keep each finding tied to the population and exposure window that produced it. Narrower, context-specific interpretation is more useful than an inappropriate direct comparison that averages incompatible studies.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- ATTR-ACT: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- ATTRibute-CM: Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. New England Journal of Medicine
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.